PortalPublikationenDNA vaccination

DNA vaccination

Standard

DNA vaccination : using the patient's immune system to overcome cancer. / Eschenburg, Georg; Stermann, Alexander; Preissner, Robert; Meyer, Hellmuth-Alexander; Lode, Holger N.

in: Clin Dev Immunol, Jahrgang 2010, 01.01.2010, S. 169484.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Eschenburg, G, Stermann, A, Preissner, R, Meyer, H-A & Lode, HN 2010, 'DNA vaccination: using the patient's immune system to overcome cancer', Clin Dev Immunol, Jg. 2010, S. 169484. https://doi.org/10.1155/2010/169484

APA

Eschenburg, G., Stermann, A., Preissner, R., Meyer, H-A., & Lode, H. N. (2010). DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol, 2010, 169484. https://doi.org/10.1155/2010/169484

Vancouver

Eschenburg G, Stermann A, Preissner R, Meyer H-A, Lode HN. DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol. 2010 Jan 1;2010:169484. https://doi.org/10.1155/2010/169484

Bibtex

@article{4bc75ff2cab940d39e5d83af8583507b,
title = "DNA vaccination: using the patient's immune system to overcome cancer",
abstract = "Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.",
keywords = "Antigens, Neoplasm, Cancer Vaccines, DNA, Neoplasm, Humans, Immunity, Cellular, Immunity, Humoral, Neoplasms, Vaccination, Vaccines, DNA",
author = "Georg Eschenburg and Alexander Stermann and Robert Preissner and Hellmuth-Alexander Meyer and Lode, {Holger N}",
year = "2010",
month = jan,
day = "1",
doi = "10.1155/2010/169484",
language = "English",
volume = "2010",
pages = "169484",

}

RIS

TY - JOUR

T1 - DNA vaccination

T2 - using the patient's immune system to overcome cancer

AU - Eschenburg, Georg

AU - Stermann, Alexander

AU - Preissner, Robert

AU - Meyer, Hellmuth-Alexander

AU - Lode, Holger N

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.

AB - Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.

KW - Antigens, Neoplasm

KW - Cancer Vaccines

KW - DNA, Neoplasm

KW - Humans

KW - Immunity, Cellular

KW - Immunity, Humoral

KW - Neoplasms

KW - Vaccination

KW - Vaccines, DNA

U2 - 10.1155/2010/169484

DO - 10.1155/2010/169484

M3 - SCORING: Journal article

C2 - 21197271

VL - 2010

SP - 169484

ER -